There are estimated to be more than 7000 rare genetic diseases (RGDs), which are defined as affecting less than 1 in 2000 people in Europe, many of which are monogenic. Although rare individually, collectively they affect 1 in 50 individuals. Diagnosis of these diseases is often very difficult and patients can remain undiagnosed or diagnosis […]
Spago Nanomedical AB (publ) today announced the publication of data on the composition, stability, and mode of action for its leading candidate drug 177Lu-SN201.
According to the World Health Organization, almost 15% of the world’s population is living with mental illness. We have medications that can be effective, but outcomes can vary. We caught up with Heather Read-Harper (Beckman Coulter) to find out more about the value of therapeutic drug monitoring in treating mental health disorders.
Autoantibodies against M-type phospholipase A2 receptors (PLA2Rab) are a central biomarker for diagnosis and monitoring of primary membranous nephropathy (pMN). PLA2Rab detection has recently been incorporated into the new KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. Diagnosis of pMN can now be made without biopsy if PLA2Rab are present alongside corresponding clinical […]
Enhanced leakiness of the blood–brain barrier has been associated with neurodegenerative disease, and assessing this leakiness has even been suggested as a possible method for early diagnosis of such disease. In light of the recent promising results from the lecanemab therapy for Alzheimer’s disease, CLI caught up with Dr Fiona McLean (University of Dundee, UK) […]
Awareness of the utility of wastewater for epidemiology was raised during the recent COVID-19 pandemic. CLI caught up with Dr Andrew Singer (UK Centre for Ecology & Hydrology) to find out more about the development of wastewater-based epidemiology and what it can do for us.
In September, the companies Eisai and Biogen announced good news about the results of their ‘Clarity AD’ clinical trial of their drug lecanemab (https://www.eisai.com/news/2022/news202271.html).
In their aim to support researchers and clinicians, companies such as Thermo Fisher Scientific are also at the forefront of their own R&D. CLI caught up with Dr Edward Goucher, Senior Manager of Business Development, to discuss their new developments.
Frinculescu A, Coombes G, Shine T et al. Drug Test Anal 2022;doi:10.1002/dta.3277 Increasing popularity and known shortfalls in the regulation of electronic cigarettes (ECs) emphasizes the urgent need for closer content monitoring and for comprehensible information on their possible health effects.
by Xijun Min, Dr Yan Li, Liuyan Chen, Chengwei Yao, Dr Xi Qin As a traditional tumour marker for the diagnosis of early primary hepatic carcinoma (PHC), alpha fetoprotein (AFP) has a low positive rate. Serum glypican 3 (GPC3) is a novel biomarker, and the combined examination of GPC3 and AFP will provide a new […]
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.